Rallybio Corporation (RLYB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rallybio Corporation (RLYB) trades at $15.80 with AI Score 31/100 (Grade D). Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Market cap: $91.64M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for RLYB: RLYB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RLYB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RLYB: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Rallybio Corporation (RLYB) Healthcare & Pipeline Overview
Rallybio Corporation is a clinical-stage biotechnology company focused on developing life-transforming therapies for patients with severe and rare diseases, primarily targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT) with its lead product candidates, RLYB212 and RLYB211, and leveraging strategic alliances for novel antibody-based therapeutics.
What Is the Investment Thesis for RLYB?
Rallybio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on rare diseases, particularly FNAIT, offers the potential for significant revenue generation if RLYB212 and RLYB211 successfully complete clinical trials and gain regulatory approval. The ongoing Phase II trial for RLYB212 is a key catalyst to watch. The company's collaborations with AbCellera, Exscientia, and Johnson & Johnson provide access to innovative technologies and expand its pipeline. However, the company's negative profit margin of -1046.4% and small market cap of $91.64M indicate substantial financial risk. The negative beta of -1.20 suggests the stock moves inversely to the market, which could be beneficial during market downturns but also limits upside potential during bull markets. Successful clinical trial outcomes and strategic partnership advancements are critical for driving shareholder value.
Based on FMP financials and quantitative analysis
RLYB Key Highlights
- Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases.
- Lead product candidate RLYB212 is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Gross margin of 99.7% suggests strong potential profitability if products reach commercialization.
- Market capitalization of $91.64M indicates a small-cap company with significant growth potential but also higher risk.
- Strategic alliances with AbCellera, Exscientia, and Johnson & Johnson enhance drug discovery and development capabilities.
Who Are RLYB's Competitors?
RLYB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | $313.04 | +0.08% | $41.79B | 95 |
| CRSP CRISPR Therapeutics AG | $61.78 | +2.83% | $5.96B | 44 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RLYB's Key Strengths?
- Focus on rare diseases with unmet medical needs.
- Strong pipeline of product candidates in various stages of development.
- Strategic alliances with leading pharmaceutical and biotechnology companies.
- Experienced management team with a track record of success.
What Are RLYB's Weaknesses?
- Limited financial resources compared to larger pharmaceutical companies.
- High dependence on the success of its lead product candidates.
- Long development timelines and regulatory hurdles.
- Negative profit margin.
What Could Drive RLYB Stock Higher?
- RLYB212 Phase II clinical trial data readout for FNAIT prevention.
- Initiation of clinical trials for RLYB114 in complement-mediated ophthalmic diseases.
- Advancement of RLYB116 through further clinical trials for diseases of complement dysregulation.
- Preclinical development of RLYB332 for severe anemia.
What Are the Key Risks for RLYB?
- Negative return on equity (-14.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for RLYB212 or other product candidates.
- Unfavorable clinical trial results.
- Competition from larger pharmaceutical companies with more resources.
- Dependence on strategic alliances for drug discovery and development.
- Changes in the regulatory landscape.
What Are the Growth Opportunities for RLYB?
- RLYB212 for FNAIT Prevention: RLYB212, currently in Phase II clinical trials, represents a significant growth opportunity. FNAIT affects approximately 1 in 1,000 pregnancies, creating a substantial unmet medical need. Successful completion of the Phase II trial and subsequent regulatory approval could lead to significant market penetration and revenue generation. The timeline for potential commercialization is dependent on trial outcomes, with potential market entry within the next 3-5 years, pending positive results and regulatory approval.
- RLYB114 for Complement-Mediated Ophthalmic Diseases: RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule, is in preclinical development for the treatment of complement-mediated ophthalmic diseases. This represents a significant market opportunity, as these diseases often lead to vision loss and have limited treatment options. The ophthalmic disease market is projected to grow, driven by an aging population and increasing prevalence of conditions like age-related macular degeneration. Preclinical development is ongoing, with potential for clinical trials to commence within the next 2 years.
- RLYB116 for Diseases of Complement Dysregulation: RLYB116, an inhibitor of complement component 5 (C5), targets several diseases of complement dysregulation and has completed phase 1 trial. These diseases often have limited treatment options and can be life-threatening. Successful development and commercialization of RLYB116 could address a significant unmet medical need and generate substantial revenue. Further clinical trials are planned, with potential for market entry within the next 4-6 years, pending positive results and regulatory approval.
- RLYB332 for Severe Anemia: RLYB332, a preclinical antibody, is being developed for the treatment of severe anemia with ineffective erythropoiesis and iron overload. This represents a significant market opportunity, as severe anemia can have debilitating effects on patients. The anemia market is projected to grow, driven by an aging population and increasing prevalence of chronic diseases. Preclinical development is ongoing, with potential for clinical trials to commence within the next 2-3 years.
- Strategic Alliances for Novel Therapies: Rallybio's strategic alliances with companies like AbCellera and Exscientia provide access to innovative technologies and expand its pipeline. These collaborations could lead to the discovery and development of novel therapies for rare diseases, creating additional growth opportunities for the company. The timeline for potential commercialization is dependent on the success of these collaborations, with potential for new product launches within the next 5-7 years.
What Opportunities Does RLYB Have?
- Potential for orphan drug designation and accelerated regulatory pathways.
- Expanding its pipeline through strategic alliances and acquisitions.
- Addressing unmet medical needs in underserved patient populations.
- Growing demand for therapies for rare diseases.
What Threats Does RLYB Face?
- Competition from larger pharmaceutical companies with more resources.
- Failure to obtain regulatory approval for its product candidates.
- Unfavorable clinical trial results.
- Changes in the regulatory landscape.
What Are RLYB's Competitive Advantages?
- Patent protection for its novel therapeutic candidates.
- Orphan drug designation for rare disease therapies, providing market exclusivity.
- Specialized expertise in developing therapies for rare diseases.
- Strategic alliances with leading pharmaceutical and biotechnology companies.
What Does RLYB Do?
Founded in 2018 and headquartered in New Haven, Connecticut, Rallybio Corporation is a clinical-stage biotechnology company dedicated to identifying and developing therapies for patients suffering from severe and rare diseases. The company's primary focus is on addressing unmet medical needs in areas such as hematology, immuno-inflammation, and metabolic disorders. Rallybio's lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody currently in Phase II clinical trials for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but serious condition that can cause bleeding in newborns. Another key asset is RLYB211, also aimed at preventing FNAIT. Beyond FNAIT, Rallybio is developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for complement-mediated ophthalmic diseases. RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation, has completed phase 1 trial. Additionally, RLYB332, a preclinical antibody, is being developed for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has established strategic alliances with companies like AbCellera to discover and develop novel antibody-based therapeutics for rare diseases, Exscientia for small molecule therapeutics, and Johnson & Johnson for therapeutic solutions related to FNAIT. These collaborations highlight Rallybio's commitment to innovation and its strategy of leveraging external expertise to accelerate drug development.
What Products and Services Does RLYB Offer?
- Develops therapies for severe and rare diseases.
- Focuses on hematology, immuno-inflammation, and metabolic disorders.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with other companies to discover and develop novel therapies.
- Seeks regulatory approval for its products from agencies like the FDA.
- Commercializes its approved products to treat patients in need.
How Does RLYB Make Money?
- Develops and patents novel therapeutic candidates.
- Out-licenses or co-develops products with larger pharmaceutical companies.
- Generates revenue through product sales upon regulatory approval.
- Forms strategic alliances to share development costs and risks.
What Industry Does RLYB Operate In?
Rallybio operates within the biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. The rare disease market, where Rallybio focuses, is attractive due to the potential for orphan drug designation and accelerated regulatory pathways. Competition is intense, with both large pharmaceutical companies and smaller biotechs vying for market share. Rallybio's success depends on its ability to successfully navigate the clinical trial process, secure regulatory approvals, and commercialize its products effectively.
Who Are RLYB's Key Customers?
- Patients suffering from severe and rare diseases.
- Healthcare providers who prescribe and administer Rallybio's therapies.
- Hospitals and clinics that use Rallybio's products.
- Pharmaceutical companies that partner with Rallybio.
ROE -14%Key Financial Metrics
Return on equity for Rallybio Corporation stands at -14.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.
Rallybio Corporation (RLYB) Valuation Context
Valued at $91.64M, RLYB is classified as a micro-cap stock. Relative to its peer group, RLYB's quantitative score of 31/100 is below the peer average of 73/100.
Company Profile
Rallybio Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Stephen Uden. RLYB has traded publicly since 2021.
F-Score 1/9Financial Health
Rallybio Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.54 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Rallybio Corporation revenue of about $80K for fiscal 2026, with EPS near $-5.52.
RLYB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Rallybio's pipeline and growth potential, indicating belief in the company's future success.
- Community sentiment has leaned positive, with discussions highlighting the company's innovative therapies and their potential impact on rare diseases.
- The recent partnerships and collaborations have enhanced Rallybio's credibility and market position, attracting attention from both investors and healthcare professionals.
- Analysts are optimistic about the upcoming clinical trial results, which could validate the company's approach and drive interest.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with many investors wary of potential challenges from established players.
- Social sentiment has shown some skepticism regarding the timeline for product development, with discussions around delays impacting investor confidence.
- Market perception reflects a cautious stance, as some investors are uncertain about the scalability of Rallybio's solutions in a rapidly evolving industry.
- Recent fluctuations in broader market conditions have led to increased volatility, causing some investors to reassess their positions in biotech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
RLYB Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Dec 7, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jun 13, 2022
RLYB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RLYB.
Price Targets
Wall Street price target analysis for RLYB.
RLYB MoonshotScore
What does this score mean?
The MoonshotScore rates RLYB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stephen Uden
CEO
Stephen Uden serves as the CEO of Rallybio Corporation. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Rallybio, he held leadership positions at various companies, where he was responsible for overseeing drug development, commercialization, and strategic partnerships. He brings a wealth of knowledge in clinical development and regulatory affairs to Rallybio.
Track Record: Under Stephen Uden's leadership, Rallybio has advanced its lead product candidates through clinical trials and established strategic alliances with key industry players. He has overseen the company's growth and expansion, focusing on building a strong pipeline of therapies for rare diseases. His strategic decisions have been instrumental in positioning Rallybio for future success.
Rallybio Corporation Healthcare Stock: Key Questions Answered
What does Rallybio Corporation do?
Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing life-transforming therapies for patients suffering from severe and rare diseases. The company's lead product candidates, RLYB212 and RLYB211, are designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). Rallybio also has a pipeline of other product candidates in preclinical and clinical development targeting complement-mediated ophthalmic diseases, diseases of complement dysregulation, and severe anemia. Rallybio leverages strategic alliances to enhance its drug discovery and development capabilities.
What do analysts say about RLYB stock?
Analyst coverage of Rallybio is limited due to its small market capitalization and clinical-stage nature. However, analysts generally view the company's focus on rare diseases and its pipeline of product candidates as promising. Key valuation metrics include potential peak sales for RLYB212 and other product candidates, as well as the company's cash runway. Growth considerations include successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst ratings and price targets vary depending on individual assessments of these factors.
What are the main risks for RLYB?
Rallybio faces several key risks, including the potential failure to obtain regulatory approval for its product candidates, unfavorable clinical trial results, competition from larger pharmaceutical companies, dependence on strategic alliances, and changes in the regulatory landscape. The company's limited financial resources also pose a risk, as it may need to raise additional capital to fund its operations. Additionally, the company's focus on rare diseases means that its market potential is limited compared to companies targeting more common diseases.
How does Rallybio Corporation manage patent expiration risks?
As a clinical-stage biotechnology company, Rallybio manages patent expiration risks by actively pursuing patent protection for its novel therapeutic candidates and formulations. The company also employs lifecycle management strategies to extend the exclusivity of its products, such as developing new formulations or indications. Furthermore, Rallybio monitors the competitive landscape and anticipates potential biosimilar competition to mitigate the impact of patent expirations. The success of these strategies is crucial for maintaining market share and profitability.
What is Rallybio Corporation's drug pipeline status?
Rallybio Corporation's drug pipeline includes RLYB212, a monoclonal anti-HPA-1a antibody in Phase II clinical trial for FNAIT prevention, and RLYB211, also for FNAIT prevention. RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule, is in preclinical development for complement-mediated ophthalmic diseases. RLYB116, a C5 inhibitor, has completed phase 1 trial for complement dysregulation diseases. RLYB332, an antibody, is in preclinical development for severe anemia. Upcoming catalysts include data readouts from the RLYB212 Phase II trial and potential initiation of clinical trials for RLYB114.
What are the key factors to evaluate for RLYB?
Rallybio Corporation (RLYB) holds an AI score of 31/100 (low). Not financial advice.
How frequently does RLYB data refresh on this page?
RLYB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RLYB's recent stock price performance?
Rallybio Corporation (RLYB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare diseases with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.